GCM
FLGT icon

Graham Capital Management’s Fulgent Genetics FLGT Stock Holding History

Graham Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-44,328
Closed -$1.38M – 1077
2023
Q1 		$1.38M Sell
44,328
-42,375
-49% -$1.36M 0.04% 388
2022
Q4 		$2.58M Buy
+86,703
New +$3.1M 0.08% 187
2022
Q2 		– Sell
-4,721
Closed -$294K – 1083
2022
Q1 		$294K Buy
+4,721
New +$311K 0.01% 739

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Graham Capital Management's FLGT Position: Q2 2023 in Review

Graham Capital Management sold out of Fulgent Genetics (FLGT) in Q2 2023, closing a stake of 44,328 shares — an estimated $1.38M sold.

Graham Capital Management first reported a position in FLGT in Q1 2022 and held it in 3 quarters. The position peaked at $2.58M in Q4 2022. 214 funds tracked by Wall St. Rank hold FLGT as of Q2 2023.

  • Graham Capital Management reported no remaining Fulgent Genetics position as of Q2 2023 after selling out during the quarter.
  • Graham Capital Management sold 44,328 Fulgent Genetics shares in Q2 2023, an estimated $1.38M.
  • Graham Capital Management first reported a position in Fulgent Genetics in Q1 2022 and held it in 3 quarters.
  • Graham Capital Management's Fulgent Genetics position peaked at $2.58M in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2023.

Based on Graham Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.